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Abstract 
Background and Objective: Nonacog beta pegol (N9- GP) and recombinant factor IX- 
Fc fusion protein (rFIXFc) are extended half- life rFIX compounds. We report the first 
single- dose pharmacokinetic trial of N9- GP and rFIXFc.
Patients/Methods: Paradigm 7 was a multicenter, open- label, randomized, crossover trial 
in previously treated (>150 exposure days) adults with congenital hemophilia B (FIX activ-
ity ≤2%). Patients received single intravenous injections (50 IU/kg) of N9- GP and rFIXFc 
with at least 21 days between doses. Plasma FIX activity, predose, and at serial time 
points up to 240 hours postdose, was measured using validated one- stage clotting assays 
(SynthAFax for N9- GP; Actin FSL for rFIXFc) and a chromogenic assay (ROX  factor IX) 
with normal human plasma as calibrator. The primary endpoint was area under the FIX 
activity–time curve from 0 to infinity, dose- normalized to 50 IU/kg (AUC0-inf,norm).
Results: Fifteen patients received study treatment. Based on FIX activity results from the 
one- stage clotting assays, estimated AUC0-inf,norm was significantly greater for N9- GP 
than rFIXFc (ratio: 4.39; P < 0.0001, based on a two- sided test on 5% significance level). In 
addition, N9- GP had a longer terminal half- life, two times higher incremental recovery at 
30 minutes and maximum FIX activity (dose- normalized to 50 IU/kg) and six times higher 
FIX activity at 168 hours than rFIXFc. These findings were largely comparable with the 
chromogenic assay data and are consistent with published data for each compound.
Conclusions: In this comparison, N9- GP demonstrated favorable pharmacokinetic 
characteristics versus rFIXFc, helping clinicians to understand differences between 
N9- GP and rFIXFc.
Registration: This trial is registered with clinicaltrials.gov (NCT03075670) and the 
European Clinical Trials Database (EudraCT: 2016- 001149- 25).
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1  | INTRODUC TION
Prophylactic administration of coagulation factor is widely consid-
ered to be the current standard of care for patients with severe 
 hemophilia.1-4 To ensure optimal prophylaxis and cost- effective fac-
tor use, dosing should be tailored according to the pharmacokinetic 
(PK) properties of the factor IX (FIX) product used, as well as each 
patient's clinical situation and disease severity.5,6
Pharmacokinetic parameters are known to vary among different 
FIX products;7 it is important to understand these differences to 
 ensure successful bleed prevention and control. With the advent of 
extended half- life (EHL) recombinant FIX (rFIX) concentrates, which 
are expected to impact the hemophilia B treatment landscape pro-
foundly, PK characteristics will remain a vital influence in treatment 
decisions.1
Nonacog beta pegol (N9- GP, REFIXIA/REBINYN; Novo Nordisk 
A/S, Bagsværd, Denmark) and eftrenonacog alfa (rFIX- Fc fusion pro-
tein [rFIXFc], ALPROLIX; Bioverativ Therapeutics, Inc., Waltham, 
MA) are EHL rFIX products that use different technologies to pro-
long the half- life of FIX. N9- GP uses site- directed glycoPEGylation 
of FIX,8 while rFIXFc involves fusion of rFIX to the Fc domain of 
human immunoglobulin G1 (IgG1).9
Both N9- GP10-13 and rFIXFc14-17 showed clinical efficacy and 
favorable safety profiles in their respective clinical development 
programs. Both products also show improved PK characteristics 
when compared with non- modified (standard half- life) FIX prod-
ucts;10,11,14,15,17,18 these improvements are expected to decrease the 
burden of treatment and potentially allow patients to live a more 
physically active life.
However, published PK data for N9- GP and rFIXFc are not di-
rectly comparable due to key differences in trial designs and PK anal-
ysis methodologies.19 Therefore, the aim of this trial was to perform 
a direct, single- dose PK comparison between N9- GP and rFIXFc. 
The findings from the trial are intended to help clinicians define opti-
mal treatment strategies for patients with hemophilia B.
2  | METHODS
2.1 | Trial design
paradigm 7 was a multicenter, multinational, open- label, rand-
omized, crossover trial (Figure 1), conducted between March 7, 
and December 8, 2017. Total trial duration for each patient was 
approximately 32 days, excluding a 28- day screening period. The 
trial consisted of one screening visit and two PK sessions, each of 
which comprised eight visits. Randomization was performed via 
the Interactive Web Response System and was balanced with re-
spect to period (1:1, block size of 2). At visit 2, after randomization, 
 patients received a single 50- IU/kg dose of either N9- GP or rFIXFc; 
at least 21 days after this first dose, patients received a single dose 
of the other product. Each dose administration was preceded by a 
minimum 96- hour washout period from nonmodified FIX products 
(if administered); the use of commercial EHL rFIX products was not 
permitted during the trial.
The trial was conducted in accordance with Good Clinical Practice 
regulations and the ethical principles stated in the Declaration of 
Helsinki.20,21 Approval from relevant institutional review boards and 
independent ethics committees was obtained and all patients pro-
vided written informed consent before the start of the trial.
2.2 | Trial objectives
The primary objective of paradigm 7 was to compare the single- dose 
PK of N9- GP and rFIXFc in patients with hemophilia B. The second-
ary objective was to evaluate the safety of both treatments.
2.3 | Patients
Investigators enrolled male patients aged 18- 70 years with congeni-
tal hemophilia B (FIX 2% or less) and more than 150 exposure days to 
any standard half- life FIX product. Patients who had current or past 
history of FIX inhibitors (at least 0.6 Bethesda Units), were immuno-
compromised (CD4+ T cells 200/μL or fewer), or had a body mass 
index greater than 35 kg/m2 were excluded from the trial.
2.4 | PK assessments
Each PK session was 10 days long and consisted of eight visits 
(Figure 1). Blood samples were collected for PK assessment at 14 
time- points over each 10- day PK session: predose, 10 and 30 min-
utes, and 1, 3, 6, 8, 24, 48, 96, 144, 168, 192, and 240 hours postdose.
FIX activity was measured using the one- stage clotting and 
chromogenic assays performed on a Siemens BCS- XP analyzer 
(Siemens, Marburg, Germany). Normal human plasma (NHP) stan-
dards, calibrated against the World Health Organization inter-
national FIX standard, were used to calibrate all assays. For the 
one- stage clotting assays, the activated partial thromboplastin time 
(aPTT) reagents were selected by referring to the product label and/
Essentials
• Published PK data for N9-GP and rFIXFc (both EHL rFIX drugs) are not directly comparable.
• paradigm 7 was the first randomized, single-dose trial between two EHL compounds.
• N9-GP demonstrated consistently favorable PK characteristics versus rFIXFc.
• These findings will help clinicians understand PK differences between EHL rFIX products.
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or published literature recommendations for each product;8,22,23 
SynthAFax (Instrumentation Laboratory, Bedford, MA) was used for 
N9- GP and Actin FSL (Siemens, Marburg, Germany) for rFIXFc. To 
date, chromogenic assays had not been used in any clinical trials with 
rFIXFc; however, given that the ROX factor IX (Rossix AB, Mölndal, 
Sweden) kit has been previously qualified for measuring N9- GP,24 it 
was subsequently qualified for measuring rFIXFc in the current trial 
and selected as the chromogenic assay for both products.
2.5 | Endpoints
The primary endpoint was area under the FIX activity–time curve from 
0 to infinity, dose- normalized to 50 IU/kg (AUC0-inf,norm). Secondary 
PK endpoints included maximum FIX activity dose- normalized to 
50 IU/kg (Cmax,norm), terminal half- life (t½), incremental recovery at 
30 minutes (IR30min), clearance (CL), FIX activity at 168 hours (C168h), 
and apparent volume of distribution at steady state (Vss). FIX activity 
at 240 hours (C240h) was assessed as an additional endpoint. All PK 
endpoints were calculated based on plasma FIX activity measured 
from time 0 to 240 hours postdose. Dose normalization to 50 IU/
kg (for AUC0-inf,norm and Cmax,norm) was performed by multiplying the 
value for the non- normalized parameter by 50 and dividing by the 
actual injected dose. The secondary safety endpoint was number of 
adverse events (AEs).
2.6 | Statistical analyses
Based on data from the pivotal, phase III trial of N9- GP,11 the within- 
patient variation in terms of geometric coefficient of variation (CV) 
was ≤20%.
Assuming that data are log- normal distributed, the 90% confi-
dence interval (CI) of the AUC ratio between N9- GP and rFIXFc would 
be [0.87; 1.15] times the estimated AUC ratio with 12 patients com-
pleting. Thus, 12 patients completing both PK sessions was consid-
ered necessary to provide an adequate comparison of the PK between 
 N9- GP and rFIXFc.
All PK endpoints were log- transformed before being analyzed 
using a mixed- effects model that included product and period as 
fixed effects and patients as a random effect. Such a model allowed 
adjustments to be made for patient variability, enabled inclusion of 
patients with data for only one product/period and precluded the 
requirement for a pairwise comparison between the two periods for 
each patient. Estimates with two- sided 95% CIs were provided for 
each treatment, back- transformed to the original scale. The two- 
sided 95% CIs for the comparison between treatments (expressed 
as a ratio) were provided together with the P- value. All PK endpoints 
were derived using noncompartmental methods and all analyses 
were performed at the 5% significance level.
All patients exposed to the trial products were included in the 
safety analysis set; all patients with at least one evaluable PK profile 
were included in the full analysis set (used for the primary PK analy-
sis). AEs were summarized and listed descriptively.
2.7 | Data- sharing statement
The trial sponsor's policy on data sharing may be found at https://
www.novonordisk-trials.com/how-access-clinical-trial-datasets.
3  | RESULTS
3.1 | Patient population and demographics
Patient demographics are presented in Table 1. In total, 15 patients 
were recruited from three countries (Germany, Switzerland, and the 
United States) and received single doses of N9- GP and rFIXFc. Eight 
patients received N9- GP first, then rFIXFc; seven received rFIXFc 
first, then N9- GP. Mean age was 39.7 years (standard deviation: 
15.5 years) and most patients were Caucasian (11 of 15; 73.3%).
One patient experienced a breakthrough bleed after dosing with 
rFIXFc, which he self- treated with the commercial rFIXFc product 
(prohibited per the trial protocol). After his PK profile was shown to 
be affected, this patient was excluded from the PK analysis; thus, 
the full analysis set comprised 14 patients. In addition, one patient 
missed the last two sampling time- points (192 and 240 hours) for 
the N9- GP PK session and another patient missed the last two sam-
pling time- points for the rFIXFc PK session. These patients were 
excluded from the analyses for AUC0-inf,norm, t½, C168h, C240h, CL, 
and Vss because the missing values could have potentially affected 
the derivation of these endpoints. No patients were withdrawn 
from the trial.
F IGURE  1 Trial design and 
pharmacokinetic sampling. Doses of 
each trial product were separated by at 
least 21 d; each dose administration was 
preceded by a 96- h washout from non- 
modified FIX products. FIX, factor IX; PK, 
pharmacokinetic; rFIXFc, recombinant 
factor IX- Fc fusion protein; V, visit
         Total N = 15
Randomized (1:1)
PK session 1
(10 d)
PK session 2
(10 d)
n = 8
n = 7
Washout
(≥4 d) End of trial
N9-GP 
rFIXFc 
N9-GP 
rFIXFc 
≥21 d
V2V1 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17
Dosing
(single dose)
Washout
(≥4 d)
Dosing
(single dose)
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3.2 | PK assessment
Mean FIX activity profiles for N9- GP and rFIXFc, measured 
using the one- stage clotting and chromogenic assays calibrated 
with NHP, are presented in Figure 2. Interpatient variability was 
low for both products and, for N9- GP, the FIX activity profile 
measured using the one- stage clotting assay was similar when 
calibrated by either NHP or a product- specific standard (data not 
shown).
Geometric mean values and geometric coefficients of variation 
for pre- dose FIX activity and the derived PK endpoints are shown in 
Table 2. The results from the mixed- effects model are presented in 
Figure 3.
Based on FIX activity results from one- stage clotting assays 
(Figure 2A), estimated AUC0–inf,norm was more than four times larger 
for N9- GP versus rFIXFc (96.6 vs 22.0 IU*h/mL; estimated ratio: 
4.39 [95% CI: 4.06- 4.75]; P < 0.001) (Figure 3). Results obtained with 
the chromogenic assay (Figure 2B,C) were comparable (3.24 [95% CI: 
2.94- 3.57]; P < 0.0001).
Overall, N9- GP demonstrated favorable PK characteristics com-
pared with rFIXFc (Figure 3). Based on results using the one- stage 
clotting assay, Cmax,norm, and IR30min were both twice as high with 
N9- GP versus rFIXFc (estimated ratio: 2.02 and 2.20, respectively; 
P < 0.0001 for both), t½ was slightly longer (estimated ratio: 1.22; 
P < 0.001) and FIX activity was approximately six times higher at both 
168 hours (0.187 vs 0.032 IU/mL; estimated ratio: 5.80; P < 0.0001), 
and 240 hours (0.116 vs 0.019 IU/mL; estimated ratio: 6.12; 
P < 0.0001). Moreover, CL was four times lower (estimated ratio: 
0.23; P < 0.0001) and Vss was three times lower (estimated ratio: 0.33; 
P < 0.0001). For all secondary and additional PK endpoints, results 
obtained using the chromogenic assay were comparable with results 
from the one- stage clotting assay.
For each patient, N9- GP had a higher IR30min, C168h, and C240h, as 
well as a greater AUC0–inf,norm, than rFIXFc.
3.3 | Safety
No serious AEs were reported in the trial and no patients devel-
oped inhibitors. Overall, five AEs were reported in four patients 
during the PK sessions, while three AEs occurred in two patients 
during the washout period between PK sessions. Three AEs were 
reported in two patients during the N9- GP PK session: fatigue and 
headache in one patient and fatigue in the other patient; all three 
AEs were considered mild in severity. Two AEs were reported 
in two patients after receiving rFIXFc: mild nasopharyngitis and 
moderate left elbow pain. No AEs were judged to be related to 
trial products.
4  | DISCUSSION
Extended half- life rFIX concentrates offer several potential benefits 
to patients with hemophilia B, particularly for chronic prophylactic 
use, including reduced dosing frequency, higher FIX activity levels, 
improved patient adherence, and enhanced quality of life.1 However, 
the availability of EHL rFIX concentrates, which differ from one 
 another in terms of half- life extension technology and manufactur-
ing processes, raises key questions for clinicians; these include how 
to choose the most suitable product for their patients and what the 
cost implications will be.1
A thorough knowledge of product PK will not only help clinicians 
to choose a suitable EHL product, but will also help to determine 
the most suitable treatment regimen for each patient depending 
on an individual's needs, providing the most effective hemostatic 
coverage.25,26
Previously published data from clinical trials have suggested 
a superior PK profile for N9- GP versus rFIXFc. In the respective 
phase III trials that assessed once- weekly prophylaxis regimens 
for each compound,8,9,11,15 greater AUC0-inf, and longer t½ were 
reported for N9- GP 40 IU/kg than for rFIXFc 50 IU/kg (arithmetic 
means: 86.89 vs 16.19 IU*h/mL and 85.1 vs 82.1 hours, respec-
tively). Furthermore, a higher IR30min was reported for N9- GP than 
for rFIXFc (0.02 vs 0.009 [IU/mL]/[IU/kg]), while reported CL was 
lower (0.43 vs 3.2 mL/h/kg).
However, due to key differences in the trial designs for each of these 
previous trials, the data are not directly comparable.11 Therefore, this 
first direct comparison offers valuable insight for clinicians seeking to 
TABLE  1 Patient demographics
Characteristic Value
Number of patients, N 15
Age, y
Mean (SD) 39.7 (15.5)
Range 21- 65
Height, m
Mean (SD) 1.76 (0.08)
Range 1.65- 1.89
Body weight, kg
Mean (SD) 79.0 (16.7)
Range 57.3- 117
BMI, kg/m2
Mean (SD) 25.3 (4.0)
Range 19.2- 32.9
Race, N (%)
White 11 (73.3)
Black/African American 1 (6.7)
Asian 1 (6.7)
Other 2 (13.3)
Country, N (%)
Germany 6 (40.0)
Switzerland 2 (13.3)
USA 7 (46.7)
BMI, body mass index; SD, standard deviation.
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understand the differences in PK characteristics between the two EHL 
rFIX products. In the current trial, the favorable PK characteristics of 
N9- GP relative to rFIXFc, as suggested by previous trials, appear to have 
been confirmed. Compared with rFIXFc, N9- GP had approximately four 
times larger AUC0-inf,norm, two times higher IR30min and Cmax,norm, four 
times lower CL, slightly longer t½, and six times higher C168h and C240h. 
Results for all PK endpoints were consistent using both the one- stage 
clotting and chromogenic assays, as well as consistent with previously 
published findings for each product.10,11,14,15
This confirmation of the favorable PK characteristics of N9- GP, 
together with the positive hemostatic efficacy reported throughout 
the paradigm clinical program,11-13 suggest that N9- GP may enable 
patients to follow similar physical activity regimens to the normal 
population, as weekly prophylaxis with 40 IU/kg elevates FIX levels 
to nonhemophilia ranges for most of the week with FIX trough levels 
in the mild hemophilic range.
Log- scale comparison of the FIX activity profiles for each  product 
(Figure 4) demonstrated that the N9- GP data fit well into a one- 
compartment model, while the rFIXFc data are best described by a 
two- or three- compartment PK model. This emphasizes the differ-
ent intercompartment distributions of each drug and is consistent 
with the observed difference in Vss, as well as the published data and 
known distribution phases for each product.14,18 However, the clini-
cal consequences of these findings are not known. After intravenous 
F IGURE  2 Mean FIX activity profiles 
following single 50- IU/kg doses of N9- GP 
and rFIXFc, measured using one- stage 
clotting and chromogenic assays. Mean 
(±SD) FIX activity profiles following single 
50- IU/kg doses of N9- GP and rFIXFc are 
shown, measured using one- stage clotting 
assays (A) and the chromogenic assay (B). 
Panel (C) collates the mean plots with 
an insert magnifying FIX activity over 
the first 24 h. The aPTT reagents used 
for the one- stage clotting assay were 
SynthAFax and Actin FSL for N9- GP and 
rFIXFc, respectively. The ROX factor IX 
kit was used for the chromogenic assay 
with both treatments. All assays were 
calibrated using NHP. aPTT, activated 
partial thromboplastin time; FIX, factor 
IX; NHP, normal human plasma; PK, 
pharmacokinetic, rFIXFc, recombinant 
factor IX- Fc fusion protein; SD, standard 
deviation
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(B) Chromogenic assay
(A) 1-stage assay
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administration, N9- GP is contained predominantly in the intravas-
cular space,18 whereas rFIXFc shows a similar vascular distribution 
to native FIX.27 However, while some preclinical data suggest an 
association between FIX tissue distribution and hemostatic protec-
tion,28 other groups have demonstrated that extravascular FIX is not 
required for hemostasis and joint healing after an injury.29 To date, 
there are no clinical data to show that extravascular distribution of 
FIX manifests in any improvements in bleeding response and patient 
outcomes. The actual impact of FIX distribution on clinical effective-
ness will require further investigation.
The current trial provides a direct PK comparison of N9- GP and 
rFIXFc; however, it should be noted that the single- dose design 
of the current trial limits correlation of the findings with previous 
 observations for treatment outcomes on routine prophylaxis. Due 
to the demanding nature of the trial protocol, it would have been 
difficult to expand the duration, patient sample size, and scope of 
the trial to include bleeding rates and patient outcomes.
The authors also acknowledge that it would have been ideal to 
base the primary analysis on a one- stage clotting assay that used 
the same aPTT reagent for both products; however, unfortunately, 
TABLE  2 Pharmacokinetic endpoints
Pharmacokinetic parameters
N9- GP rFIXFc
One- stage clotting 
assay Chromogenic assay
One- stage clotting 
assay Chromogenic assay
Pre- dose FIX activity (IU/mL)
Geometric mean (CV) 0.011 (72.2) 0.011 (62.1) 0.011 (91.8) 0.015 (106.3)
Min; max 0.005; 0.027 0.005; 0.025 0.003; 0.048 0.003; 0.084
AUC0-inf,norm, IU*h/mL*
Geometric mean (CV) 96.6 (16.7) 89.2 (17.4) 22.0 (23.7) 27.5 (23.5)
Min; max 67.4; 123.7 59.8; 109.6 16.0; 35.3 19.4; 44.0
Cmax,norm, IU/mL
Geometric mean (CV) 0.91 (11.8) 0.79 (14.5) 0.45 (18.0) 0.56 (17.6)
Min; max 0.75; 1.08 0.63; 1.05 0.35; 0.62 0.41; 0.83
t½, h*
Geometric mean (CV) 103.2 (11.5) 116.2 (12.3) 84.9 (12.7) 85.8 (16.8)
Min; max 86.0; 130.5 95.5; 138.9 73.9; 116.5 59.7; 120.6
IR30min, (IU/mL)/(IU/kg)
Geometric mean (CV) 0.017 (12.3) 0.015 (16.9) 0.008 (18.8) 0.010 (20.3)
Min; max 0.013; 0.021 0.010; 0.020 0.006; 0.011 0.006; 0.014
CL, mL/h/kg*
Geometric mean (CV) 0.52 (16.7) 0.56 (17.3) 2.25 (25.1) 1.78 (25.8)
Min; max 0.40; 0.74 0.46; 0.84 1.32; 3.13 1.02; 2.58
C168h, IU/mL*
Geometric mean (CV) 0.19 (18.1) 0.18 (15.7) 0.03 (31.2) 0.04 (29.7)
Min; max 0.12; 0.24 0.12; 0.22 0.02; 0.06 0.03; 0.08
C240h, IU/mL*
Geometric mean (CV) 0.116 (17.1) 0.114 (18.2) 0.019 (32.1) 0.024 (34.3)
Min; max 0.084; 0.143 0.078; 0.140 0.013; 0.039 0.016; 0.054
Vss, mL/kg*
Geometric mean (CV) 70.4 (20.6) 85.7 (17.8) 213.7 (23.7) 172.7 (30.2)
Min; max 54.1; 116.6 66.0; 125.1 134.2; 281.0 97.5; 277.9
The aPTT reagents used for the one- stage clotting assay were SynthAFax and Actin FSL for N9- GP and rFIXFc, respectively. The ROX factor IX kit was 
used for the chromogenic assay with both treatments. All assays were calibrated using NHP.
aPTT, activated partial thromboplastin time; AUC0-inf,norm, area under the FIX activity–time curve from 0 to infinity, dose- normalized to 50 IU/kg; C168h, 
FIX activity at 168 h; C240h, FIX activity at 240 h; CL, clearance; Cmax,norm, maximum FIX activity dose- normalized to 50 IU/kg; IR30min, incremental re-
covery at 30 min; CV, geometric coefficient of variation; NHP, normal human plasma; PK, pharmacokinetic; rFIXFc, recombinant factor IX- Fc fusion 
protein; t½, terminal half- life; Vss, apparent volume of distribution at steady state.
*N = 12; two patients missed the last two PK time- points and were excluded from the analysis for these parameters. 
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there is not a single aPTT reagent that could be used to measure 
both products and allow a more robust head- to- head comparison. 
A previously published field study by Sommer et al showed that a 
one- stage clotting assay using SynthAFax overestimates FIX activity 
for rFIXFc in spiked hemophilia B plasma samples,22 and a recent 
study by Kershaw et al also reported over- recovery for rFIXFc with 
this aPTT reagent.23 Meanwhile, the field study by Sommer et al 
demonstrated that a one- stage clotting assay with Actin FSL accu-
rately reproduces the activity of rFIXFc.22 Therefore, assay reagents 
and kits were identified by available product label information and 
recommendations from published literature, and were ultimately 
selected based on successful assay qualification at the trial's onset. 
Furthermore, the PK characteristics observed for each product were 
consistent for one- stage clotting and chromogenic assays used in 
the trial, as well as with previously published information.8,9
5  | CONCLUSIONS
This direct PK comparison demonstrated that N9- GP had a higher 
IR30min and longer t½ than rFIXFc, which resulted in significantly 
larger AUC0-inf,norm and higher C168h, indicative of a favorable PK 
F IGURE  3 Analysis of PK endpoints for N9- GP versus rFIXFc, derived from FIX activity measured using one- stage clotting and 
chromogenic assays. All PK endpoints were log- transformed before being analyzed using a mixed- effects model that included product 
and period as fixed effects and patients as a random effect. Estimates with two- sided 95% CIs were provided for each treatment, back- 
transformed to the original scale; the two- sided 95% CIs for the comparisons between treatments were expressed as ratios and provided 
together with the P- values. The aPTT reagents used for the one- stage clotting assay were SynthAFax and Actin FSL for N9- GP and 
rFIXFc, respectively. The ROX factor IX kit was used for the chromogenic assay with both treatments. All assays were calibrated using 
NHP. *P < 0.0001 for all comparisons, except for t½, for which P < 0.001 for both assays. aPTT, activated partial thromboplastin time; 
AUC0-inf,norm, area under the FIX activity–time curve from 0 to infinity, dose- normalized to 50 IU/kg; C168h, FIX activity at 168 h; C240h, FIX 
activity at 240 h; CI, confidence interval; CL, clearance; Cmax,norm, maximum FIX activity dose- normalized to 50 IU/kg; FIX, factor IX; IR30min, 
incremental recovery at 30 min; NHP, normal human plasma; PK, pharmacokinetic; rFIXFc, recombinant factor IX- Fc fusion protein; t½, 
terminal half- life; Vss, apparent volume of distribution at steady state
1
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F IGURE  4 Log- scale mean FIX activity profiles following single 50- IU/kg doses of N9- GP and rFIXFc, measured using one- stage clotting 
and chromogenic assays. Log- scale mean FIX activity profiles following single 50- IU/kg doses of N9- GP and rFIXFc are shown, measured 
using one- stage clotting assays and the chromogenic assay. The aPTT reagents used for the one- stage clotting assay were SynthAFax and 
Actin FSL for N9- GP and rFIXFc, respectively. The ROX factor IX kit was used for the chromogenic assay with both treatments. All assays 
were calibrated using NHP. aPTT, activated partial thromboplastin time; FIX, factor IX; NHP, normal human plasma; rFIXFc, recombinant 
factor IX- Fc fusion protein
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profile. No safety concerns were observed during the trial for either 
treatment. These findings will help clinicians understand differences 
in PK characteristics between N9- GP and rFIXFc.
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